MENU
+Compare
PBE
ETF ticker: NYSE ARCA
AS OF
Nov 21 closing price
Price
$80.13
Change
+$1.81 (+2.31%)
Net Assets
244.2M

PBE stock forecast, quote, news & analysis

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index... Show more

Category: #Health
PBE
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for PBE with price predictions
Nov 21, 2025

PBE's RSI Indicator penetrates overbought territory

The RSI Indicator for PBE moved into overbought territory on November 21, 2025. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 22 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PBE broke above its upper Bollinger Band on November 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2025. You may want to consider a long position or call options on PBE as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PBE just turned positive on October 20, 2025. Looking at past instances where PBE's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PBE advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 236 cases where PBE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exact Sciences Corp (NASDAQ:EXAS), Illumina (NASDAQ:ILMN), Exelixis (NASDAQ:EXEL), BioCryst Pharmaceuticals (NASDAQ:BCRX).

Industry description

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Market Cap

The average market capitalization across the Invesco Biotechnology & Genome ETF ETF is 21.44B. The market cap for tickers in the group ranges from 686.52M to 181.76B. AMGN holds the highest valuation in this group at 181.76B. The lowest valued company is MYGN at 686.52M.

High and low price notable news

The average weekly price growth across all stocks in the Invesco Biotechnology & Genome ETF ETF was 3%. For the same ETF, the average monthly price growth was 10%, and the average quarterly price growth was 31%. EXAS experienced the highest price growth at 51%, while NBIX experienced the biggest fall at -2%.

Volume

The average weekly volume growth across all stocks in the Invesco Biotechnology & Genome ETF ETF was 43%. For the same stocks of the ETF, the average monthly volume growth was 91% and the average quarterly volume growth was 76%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 66
P/E Growth Rating: 54
Price Growth Rating: 43
SMR Rating: 69
Profit Risk Rating: 68
Seasonality Score: 37 (-100 ... +100)
View a ticker or compare two or three
PBE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Powershares Exchange Traded Fund Trust227 E Prairie AveWheaton
Phone
N/A
Web
www.invescopowershares.com